

Esbriet[®] (pirfenidone) – First-time generic

- On January 10, 2023, Amneal, Cipla, <u>Laurus</u> and Sandoz launched <u>AB-rated</u> generic versions of Genentech's <u>Esbriet (pirfenidone)</u> capsule.
 - <u>Accord</u> and <u>ScieGen</u> received FDA approval of AB-rated generic versions of Esbriet capsule on January 20, 2022 and August 1, 2022, respectively. Launch plans are pending.
- Esbriet is approved for the treatment of idiopathic pulmonary fibrosis.
- Pirfenidone is also available generically as <u>tablets</u> and carries the same indication as the capsule.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.